Curi Bio Inc.
Seattle, WA
- UEI
- D6VABZ7RVM84
- CAGE
- 7C8Q3
- Primary NAICS
- 334516 Analytical Laboratory Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
-
- 334516 Analytical Laboratory Instrument Manufacturing Primary
- 325414 Biological Product (except Diagnostic) Manufacturing
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration date
- Physical address
- 3000 Western Ave, Seattle, WA 98121, USA
- Website
- curibio.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 3D ipsc skeletal muscle media kits | National Institute on Drug Abuse | $17,020 | |
| High-throughput NMJ assay for botox potency screening - project summary the botulinum toxin potency assay using tissue… | National Center for Advancing Translational Sciences | $5,993,958 | |
| A cross-species preclinical platform to enhance the translation of new medicines - project description duchenne muscular… | National Center for Advancing Translational Sciences | $5,770,581 | |
| Curibio cytostretcher-1, cytostretcher-LV, and environmental control unit | National Heart Lung and Blood Institute | $50,000 | |
| Assessing drug cardiac safety with a 3D engineered cardiac muscle tissue contractility assay platform. | National Institute on Drug Abuse | $63,932 |
About Curi Bio Inc.
Curi Bio Inc. is a Seattle-based corporate entity registered in SAM.gov as a self-certified small disadvantaged business and manufacturer of goods. The company specializes in developing advanced biomedical research technologies, particularly focusing on cell-based platforms, engineered tissue systems, and innovative research instrumentation. Its primary target markets include drug development, drug safety screening, and disease modeling, with a particular emphasis on creating sophisticated cellular and tissue models using human induced pluripotent stem cells (iPSCs).
Through federal contract awards, Curi Bio Inc. has primarily provided specialized research equipment and media kits to various National Institutes of Health (NIH) agencies. These contracts include purchase orders for 3D IPSC skeletal muscle media kits, CytoStretcher devices, and a Mantarray Magnetometric Analyzer for Engineered Tissue Arrays. The contract awards, ranging from $17,020 to $172,800, have been issued by agencies such as the National Center for Advancing Translational Sciences, National Heart Lung and Blood Institute, National Institute on Drug Abuse, and the National Institute of Diabetes and Digestive and Kidney Diseases. None of these contract awards utilized set-aside designations, and they were primarily focused on providing research equipment and specialized cellular research materials.
Curi Bio Inc.'s federal grant awards demonstrate a strong focus on developing advanced preclinical screening platforms for complex medical research challenges. The company has received grants from the National Center for Advancing Translational Sciences for projects including a high-throughput neuromuscular junction assay for Botox potency screening and a cross-species preclinical platform for Duchenne Muscular Dystrophy research. Additional grants from the National Heart Lung and Blood Institute have supported research on cryopreserving stem cell-derived cardiomyocytes, maturation of cardiac cells, and predictive assessments of cardiotoxicity. The grants, ranging from cooperative agreements to project grants, aim to develop innovative platforms for drug development, therapeutic screening, and understanding complex cellular behaviors. The company has also engaged in a sub-grant award with the University of Washington focused on enhanced gene therapy research.
Quick answers
What is Curi Bio Inc.'s UEI?
Curi Bio Inc.'s Unique Entity ID (UEI) in SAM.gov is D6VABZ7RVM84.
What is Curi Bio Inc.'s CAGE code?
Curi Bio Inc.'s CAGE code is 7C8Q3.
What is Curi Bio Inc.'s primary NAICS code?
Curi Bio Inc.'s primary NAICS code is 334516 (Analytical Laboratory Instrument Manufacturing).
Where is Curi Bio Inc. located?
Curi Bio Inc.'s physical address in SAM.gov is 3000 Western Ave, Seattle, WA 98121, USA.
Is Curi Bio Inc. registered in SAM.gov?
Yes. Curi Bio Inc.'s SAM.gov registration is active through January 6, 2027.
What is Curi Bio Inc.'s most recent federal award?
Curi Bio Inc.'s most recent federal contract award is 3D ipsc skeletal muscle media kits (75N95024P00504), from National Institute on Drug Abuse, on September 4, 2024.
On GovTribe
See Curi Bio Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors